Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...153154155156157158159160161162163...10651066»
  • ||||||||||  dexamethasone / Generic mfg.
    Journal, Cytokine storm:  Immunosuppressive dead cell as lung-targeting vehicle and cytokine absorption material for cytokine storm attenuation of pneumonia. (Pubmed Central) -  Jun 12, 2023   
    After loading the anti-inflammatory drugs of dexamethasone (DEX) and baicalin (BAI), the drug-loaded dead cell (DEX&BAI/Dead cell) could first passively target to the lung after intravenous administration and quickly release the drugs under high shearing stress of pulmonary capillaries, realizing drug enrichment in the lung...With above formulation design, a synergic anti-inflammatory effect between drugs and carrier could be achieved. In a lipopolysaccharide-induced pneumonia mice model, this system could calm down the cytokine storm with high efficacy and elongate the survival of mice.
  • ||||||||||  hydrocortisone / Generic mfg., flutamide / Generic mfg.
    Trial primary completion date, Combination therapy:  Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) -  Jun 12, 2023   
    P4,  N=62, Active, not recruiting, 
    Dexamethasone increased the risk of postoperative hyperglycemia, however, no increase in surgical site infections was identified. Trial primary completion date: Jun 2022 --> Dec 2024
  • ||||||||||  tamsulosin / Generic mfg., dexamethasone / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  PROSINT: A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer (clinicaltrials.gov) -  Jun 12, 2023   
    P2,  N=30, Active, not recruiting, 
    Trial completion date: Aug 2023 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2026 | Trial primary completion date: May 2022 --> May 2026
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Enrollment closed, Enrollment change, Combination therapy:  Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) -  Jun 12, 2023   
    P1,  N=14, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Aug 2026 | Trial primary completion date: May 2022 --> May 2026 Recruiting --> Active, not recruiting | N=28 --> 14
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Clinical guideline, Review, Journal:  Systematic review of clinical practice guidelines for uveitis. (Pubmed Central) -  Jun 10, 2023   
    This may partially be due to the large number of conditions with diverse causes and clinical presentations covered by the umbrella term uveitis, which makes numerous sets of guidelines necessary. The limited pool of CPGs to select from has implications for clinicians seeking guidance on clinical care strategies for uveitis.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Addition of dexamethasone to prolong peripheral nerve blocks: a ChatGPT-created narrative review. (Pubmed Central) -  Jun 10, 2023   
    Major concerns raised by the authors included the poor search methodology, poor organization/lack of flow, inaccuracies/omissions of text or references, and lack of novelty. At this time, we do not believe ChatGPT is able to replace human experts and is extremely limited in providing original, creative solutions/ideas and interpreting data for a subspecialty medical review article.
  • ||||||||||  prednisone / Generic mfg., cyclophosphamide / Generic mfg., hydrocortisone / Generic mfg.
    ANCA ASSOCIATED VASCULITIS AFTER COVID-19 (ePoster (Virtual Only)) -  Jun 9, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2501;    
    SARS-CoV-2 infection can be a 'trigger factor' for vasculitis. ANCA-associated vasculitis should be kept in mind in patients who develop acute kidney injury after COVID-19.
  • ||||||||||  AFTER ALL A TYPICAL HUS (ePoster (Virtual Only)) -  Jun 9, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2494;    
    This case reveals the importance of requesting PCR in the stool even when the E.coli test is negative. This is of particular relevance in immunosuppressed patients.
  • ||||||||||  methylprednisolone sodium succinate / Generic mfg.
    ANCA AND IG A NEPHROPATHY: ASSOCIATION OR PROGNOSTIC FACTOR (ePoster (Virtual Only)) -  Jun 9, 2023 - Abstract #ERAEDTA2023ERA_EDTA_2292;    
    IgAN patients with ANCA positivity showed more severe clinical and histological features when compared with ANCA-negative IgAN patients and lower renal prognosis. The ANCA antibodies should be screened in patients with severe forms of IgAN.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Successful subcutaneous desensitization to Dupilumab (Poster Zone A) -  Jun 9, 2023 - Abstract #EAACI2023EAACI_2611;    
    The symptoms responded well to Chlorphenamine maleate 10 mg and Methylprednisolone 40 mg intravenously...Desloratadine 5 mg was administered 30 minutes before the procedure...To our knowledge, this is the first reported case of desensitization to Dupilumab. Because no protocols existed, we established a new rapid subcutaneous desensitization protocol, which was well tolerated by the patient and allowed her to continue the administration wih the best treatment.
  • ||||||||||  prednisolone / Generic mfg.
    Drug Reaction with Eosinophilia and Systemic Symptoms  (Poster Zone A) -  Jun 9, 2023 - Abstract #EAACI2023EAACI_2596;    
    Because no protocols existed, we established a new rapid subcutaneous desensitization protocol, which was well tolerated by the patient and allowed her to continue the administration wih the best treatment. Suspected antibiotics were suspended and oral prednisolone was initiated...
  • ||||||||||  methylprednisolone oral / Generic mfg.
    A DRESS syndrome caused by a new medicine: niraparib (Poster Zone A) -  Jun 9, 2023 - Abstract #EAACI2023EAACI_2589;    
    Suspected antibiotics were suspended and oral prednisolone was initiated... The patient had
  • ||||||||||  hydrocortisone / Generic mfg.
    Allergy induced by bethamethasone phosphate after intra-articular infiltration (Poster Zone A) -  Jun 9, 2023 - Abstract #EAACI2023EAACI_2524;    
    The patient had Hydrocortisone and methylprednisolone succinate esters are the most frequent substances triggering immediate type adverse reactions, while halogenated corticosteroids are rarely involved...The auscultation and blood oxygen levels (SpO2) were normal.
  • ||||||||||  triamcinolone acetonide / Generic mfg., 5-fluorouracil / Generic mfg.
    Journal, IO biomarker:  Deciphering the single-cell transcriptome network in keloids with intra-lesional injection of triamcinolone acetonide combined with 5-fluorouracil. (Pubmed Central) -  Jun 9, 2023   
    Schwann cell populations achieved functional changes by increasing the proportion of apoptotic or senescence-associated cell populations and reducing cell clusters that promote epidermal development and fibroblast proliferation. Our findings elucidated the molecular and cellular reprogramming of keloids by intra-lesional injection of TAC+5-FU, which will provide new insights to understand the mechanism of action and therapeutic targets.
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    Enrollment open, Surgery:  Depomedrol for Genicular Nerve Block. (clinicaltrials.gov) -  Jun 9, 2023   
    P=N/A,  N=48, Recruiting, 
    It is important to consider adrenal insufficiency in hypercalcemia of unclear etiology. Not yet recruiting --> Recruiting
  • ||||||||||  Eucrisa (crisaborole) / Pfizer
    Enrollment closed:  Steroid-reducing Effects of Crisaborole (clinicaltrials.gov) -  Jun 9, 2023   
    P4,  N=60, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy:  Use Lenalidomide (Revlimid (clinicaltrials.gov) -  Jun 9, 2023   
    P=N/A,  N=29, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Dec 2022 | Trial primary completion date: Aug 2022 --> Dec 2022
  • ||||||||||  Brukinsa (zanubrutinib) / BeiGene, Rituxan (rituximab) / Roche
    Trial suspension, Combination therapy:  Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) -  Jun 8, 2023   
    P1,  N=24, Suspended, 
    In conclusion, the uniform fabrication of microtissue constructs containing MSC spheroids with drug depots shows a potential to improve the performance of MSCs in tissue engineering. Recruiting --> Suspended
  • ||||||||||  methylprednisolone acetate / Generic mfg.
    New trial, Surgery:  Depomedrol for Genicular Nerve Block. (clinicaltrials.gov) -  Jun 8, 2023   
    P=N/A,  N=48, Not yet recruiting,